Susquehanna International Group, LLP Immunocore Holdings PLC Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$30.06 - $41.49 $661,320 - $912,780	-22,000 Reduced 23.97%	69,800 $2.17 Million
Q2 2024 Aug 15, 2024	SELL	$33.78 - $63.75 $4.04 Million - $7.62 Million	-119,600 Reduced 56.58%	91,800 $3.11 Million
Q1 2024 May 07, 2024	BUY	$60.14 - $75.36 $1.27 Million - $1.59 Million	21,100 Added 11.09%	211,400 $13.7 Million
Q4 2023 Feb 14, 2024	BUY	$42.85 - $69.5 $3.28 Million - $5.32 Million	76,500 Added 67.22%	190,300 $13 Million
Q3 2023 Nov 14, 2023	SELL	$49.5 - $66.6 $3.74 Million - $5.03 Million	-75,600 Reduced 39.92%	113,800 $5.91 Million
Q2 2023 Aug 11, 2023	BUY	$48.54 - $61.64 $368,904 - $468,464	7,600 Added 4.18%	189,400 $11.4 Million
Q1 2023 May 16, 2023	BUY	$46.12 - $65.71 $4.42 Million - $6.3 Million	95,800 Added 111.4%	181,800 $8.99 Million
Q4 2022 Feb 14, 2023	BUY	$45.51 - $65.08 $2.84 Million - $4.06 Million	62,400 Added 264.41%	86,000 $4.91 Million
Q3 2022 Nov 14, 2022	SELL	$37.34 - $57.44 $362,198 - $557,168	-9,700 Reduced 29.13%	23,600 $1.11 Million
Q2 2022 Aug 15, 2022	BUY	$25.46 - $37.72 $847,818 - $1.26 Million	33,300 New	33,300 $1.24 Million

141

41.4M

197K

451K

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.39B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.